(Q81370156)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Federico Alberici

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

L Pavone

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

G Fanti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

C Bongiovanni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

S Bonomini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

L Cristinelli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

C Buzio

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

31 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

38-44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18516705%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12032-008-9078-7

8 January 2020

exact match

0 references

cites work

Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma

1 reference

12 December 2020

Regulation of antitumour immunity by CD1d-restricted NKT cells

1 reference

12 December 2020

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial

1 reference

12 December 2020

Effectiveness of very low doses of immunotherapy in advanced renal cell cancer

1 reference

12 December 2020

Natural killer T cells as targets for therapeutic intervention in autoimmune diseases.

1 reference

12 December 2020

Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity

1 reference

12 December 2020

Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer

1 reference

12 December 2020

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer

1 reference

12 December 2020

Rapid flow cytometric assay for the assessment of natural killer cell activity

1 reference

12 December 2020

Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma

1 reference

12 December 2020

Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial.

1 reference

12 December 2020

A versatile flow cytometry-based assay for the determination of short- and long-term natural killer cell activity

1 reference

12 December 2020

Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells

1 reference

12 December 2020

Constitutive Cytokine mRNAs Mark Natural Killer (NK) and NK T Cells Poised for Rapid Effector Function

1 reference

12 December 2020

Immune rejection of a large sarcoma following cyclophosphamide and IL-12 treatment requires both NK and NK T cells and is associated with the induction of a novel NK T cell population

1 reference

12 December 2020

Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2

1 reference

12 December 2020

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Low-dose IL-2 treatment: Activation of discrete T- and NK-cell sub-populationsin vivo

1 reference

12 December 2020

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

12 December 2020

Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study

1 reference

12 December 2020

The biology of human natural killer-cell subsets

1 reference

12 December 2020

TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D

1 reference

12 December 2020

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

1 reference

12 December 2020

Natural killer lymphocytes: biology, development, and function

1 reference

12 December 2020

Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN.

1 reference

12 December 2020

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

12 December 2020

A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity

1 reference

12 December 2020

Loss of IFN-gamma production by invariant NK T cells in advanced cancer.

1 reference

12 December 2020